Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne. Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as tamoxifen.
Anastrozole was first approved for use in the United States in 1995.
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with tamoxifen.
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
- Conditions
- Interventions
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 46
- Registration Number
- NCT01215292
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
- Conditions
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 277
- Registration Number
- NCT01197170
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Anastrozole 1 mg Tablets Under Fed Conditions
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2010-11-16
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 22
- Registration Number
- NCT01183390
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed Conditions
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 36
- Registration Number
- NCT01155960
Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 36
- Registration Number
- NCT01155947
Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions
- Conditions
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 32
- Registration Number
- NCT01155089
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions
- Conditions
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 31
- Registration Number
- NCT01155102
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 8
- Registration Number
- NCT01153672
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-06-28
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 482
- Registration Number
- NCT01151215
- Locations
- 🇬🇧
Research Site, Wythenshawe, Manchester, United Kingdom
Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 71
- Registration Number
- NCT01016665
- Locations
- 🇧🇷
Sao Paulo Federal University, Sao Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.